Activin and Inhibin

PW0464, a nanomolar potent complete G protein biased ligand, is a noncatechol D1R agonist, with an EC 50 of 5.8 nM (Gs-cAMP).In VitroPW0464 (compound 24) is found to elicit complete G protein bias, showing no activity for D1R-mediated β-arrestin

PW0464, a nanomolar potent complete G protein biased ligand, is a noncatechol D1R agonist, with an EC 50 of 5.8 nM (Gs-cAMP).In VitroPW0464 (compound 24) is found to elicit complete G protein bias, showing no activity for D1R-mediated β-arrestin

PW0464, a nanomolar potent complete G protein biased ligand, is a noncatechol D1R agonist, with an EC 50 of 5.8 nM (Gs-cAMP).In VitroPW0464 (compound 24) is found to elicit complete G protein bias, showing no activity for D1R-mediated β-arrestin

(Rac)-SNC80 is a racemate of SNC80 ( HY-101202 ). SNC80 (NIH 10815) is a potent, highly selective and non-peptide δ-opioid receptor agonist with a K i of 1.78 nM and an IC 50 of 2.73 nM. SNC80 shows antinociceptive, antihyperalgesic and

(Rac)-SNC80 is a racemate of SNC80 ( HY-101202 ). SNC80 (NIH 10815) is a potent, highly selective and non-peptide δ-opioid receptor agonist with a K i of 1.78 nM and an IC 50 of 2.73 nM. SNC80 shows antinociceptive, antihyperalgesic and

(Rac)-SNC80 is a racemate of SNC80 ( HY-101202 ). SNC80 (NIH 10815) is a potent, highly selective and non-peptide δ-opioid receptor agonist with a K i of 1.78 nM and an IC 50 of 2.73 nM. SNC80 shows antinociceptive, antihyperalgesic and

(Rac)-SNC80 is a racemate of SNC80 ( HY-101202 ). SNC80 (NIH 10815) is a potent, highly selective and non-peptide δ-opioid receptor agonist with a K i of 1.78 nM and an IC 50 of 2.73 nM. SNC80 shows antinociceptive, antihyperalgesic and

(Rac)-SNC80 is a racemate of SNC80 ( HY-101202 ). SNC80 (NIH 10815) is a potent, highly selective and non-peptide δ-opioid receptor agonist with a K i of 1.78 nM and an IC 50 of 2.73 nM. SNC80 shows antinociceptive, antihyperalgesic and

(Rac)-Sograzepide is an antagonist of cholecystokinin B (CCK-B) receptor , and has the potential of reducing the secretion of gastric acid.In Vitro(Rac)-Sograzepide is an antagonist of CCK-B receptor, and has the potential of reducing the secretion

(Rac)-Sograzepide is an antagonist of cholecystokinin B (CCK-B) receptor , and has the potential of reducing the secretion of gastric acid.In Vitro(Rac)-Sograzepide is an antagonist of CCK-B receptor, and has the potential of reducing the secretion

(Rac)-Sograzepide is an antagonist of cholecystokinin B (CCK-B) receptor , and has the potential of reducing the secretion of gastric acid.In Vitro(Rac)-Sograzepide is an antagonist of CCK-B receptor, and has the potential of reducing the secretion

(Rac)-Sograzepide is an antagonist of cholecystokinin B (CCK-B) receptor , and has the potential of reducing the secretion of gastric acid.In Vitro(Rac)-Sograzepide is an antagonist of CCK-B receptor, and has the potential of reducing the secretion